CCRM supports the development of regenerative medicines and associated enabling technologies.
Location: Canada, Ontario, Old Toronto
Employees: 51-200
Phone: +1 416-978-3751
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Fight Agai... | facit.ca |
Mentions in press and media 5
| Date | Title | Description |
| 18.10.2024 | OmniaBio Announces Opening of New Commercial Manufacturing Facility in Canada, Bringing Life-Saving Cell and Gene Therapies to Patients | The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients HAMILTON, ON, Oct. 18, 2024 /PRNewswire/ -- T... |
| 09.09.2024 | Somite Therapeutics and OmniaBio Inc. Announce Collaboration to Advance Somite's Cell Therapy Flagship Program | CDMO collaboration propels cell replacement therapy targeting Duchenne muscular dystrophy forward, with consequences for the role of AI in cell therapy BOSTON and HAMILTON, Ontario, Sept. 9, 2024 /PRNewswire/ -- Somite Therapeutics, a tech-... |
| 05.05.2022 | CELL AG TECH Joins with Canadian Research Firm CCRM to Scale Cell-Based Fish Manufacturing | CULT Food Science, an alt-protein investment platform, announces its portfolio company CELL AG TECH is collaborating with the Centre for Commercialization of Regenerative Medicine (CCRM) to efficiently scale CELL AG’s cultured seafood manuf... |
| 15.06.2021 | Canadians are polite, but we’re still recruiting your biotech talent, America | Michael May Contributor Share on Twitter Michael May is the president and CEO of the Centre for Commercialization of Regenerative Medicine. Jayson Myers Contributor Share on Twitter Jayson Myers is the CEO of Next Generation Manufacturing C... |
| 05.11.2019 | Lumira Joins Financing Syndicate for Notch Therapeutics – a New Company with Revolutionary Allogeneic T Cell Technology | Toronto, ON, (GLOBE NEWSWIRE) — Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem ... |